PFE Stock Price Today Per Share: $47.51

Pfizer's share price has been on a steady upward trend in recent years, driven by strong sales of its blockbuster drugs, such as Xeljanz and Ibrance.

Key Points

• Pfizer's share price has risen by over 20% in the past year.
• The company is expected to continue to perform well in the future, driven by strong sales of its new drugs.
• Pfizer is a good investment for investors looking for a safe and reliable stock with the potential for growth.

Pfizer's Share Price History

Pfizer's share price has been on a steady upward trend in recent years. In 2018, the company's share price was $38.47. By the end of 2019, it had risen to $43.29. In 2020, the share price continued to climb, reaching $47.51 by the end of the year.

Factors Driving Pfizer's Share Price

Several factors are driving Pfizer's share price higher. First, the company has a strong pipeline of new drugs. In 2020, Pfizer launched two new drugs, Vyndaqel and Xtandi. These drugs are expected to generate significant sales in the coming years.

Second, Pfizer is benefiting from the aging population. As people get older, they are more likely to develop chronic diseases, such as cancer and heart disease. This is creating a growing demand for Pfizer's drugs.

Third, Pfizer is a well-managed company. The company has a strong track record of innovation and profitability. This has made Pfizer a favorite of investors.

Is Pfizer a Good Investment?

Pfizer is a good investment for investors looking for a safe and reliable stock with the potential for growth. The company has a strong pipeline of new drugs, is benefiting from the aging population, and is well-managed. These factors are expected to continue to drive Pfizer's share price higher in the future.

Analysts' Recommendations

Analysts are generally positive on Pfizer. The consensus recommendation is "buy." The average price target is $52.00, which represents a potential upside of over 9% from the current share price.

Risks to Consider

There are some risks to consider before investing in Pfizer. First, the company's share price is sensitive to news about its new drugs. If a new drug fails to meet expectations, the share price could decline.

Second, Pfizer faces competition from other pharmaceutical companies. If a competitor launches a new drug that is more effective or less expensive than Pfizer's drugs, the company's sales could decline.

Third, the healthcare industry is heavily regulated. Changes in regulations could impact Pfizer's business.

Conclusion

Pfizer is a good investment for investors looking for a safe and reliable stock with the potential for growth. The company has a strong pipeline of new drugs, is benefiting from the aging population, and is well-managed. These factors are expected to continue to drive Pfizer's share price higher in the future.

Pfizer's Financial Performance

Pfizer's financial performance has been strong in recent years. The company's revenue has grown by over 10% in each of the past three years. In 2020, Pfizer's revenue was $51.75 billion. The company's net income has also grown significantly in recent years. In 2020, Pfizer's net income was $10.2 billion.

Table 1: Pfizer's Financial Performance

Pfizer's New Drugs

Pfizer has a strong pipeline of new drugs. The company is currently developing over 20 new drugs for a variety of diseases, including cancer, heart disease, and Alzheimer's disease.

Some of Pfizer's most promising new drugs include:

• Vyndaqel: A new drug for the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL).
• Xtandi: A new drug for the treatment of prostate cancer.
• Lorbrena: A new drug for the treatment of non-small cell lung cancer (NSCLC).

These drugs have the potential to generate significant sales for Pfizer in the coming years.

Table 2: Pfizer's New Drugs

Pfizer's Competition

Pfizer faces competition from other pharmaceutical companies, such as Johnson & Johnson, Merck, and Novartis. These companies are also developing new drugs for a variety of diseases.

Pfizer's competitive advantage lies in its strong pipeline of new drugs and its ability to bring new drugs to market quickly. The company has a track record of developing and commercializing successful drugs, such as Lipitor and Viagra.

Table 3: Pfizer's Competitors

Pfizer's Outlook

Pfizer's outlook is positive. The company has a strong pipeline of new drugs, is benefiting from the aging population, and is well-managed. These factors are expected to continue to drive Pfizer's share price higher in the future.

Table 4: Pfizer's Outlook

Analysts' Price Targets

Analysts are generally positive on Pfizer. The consensus recommendation is "buy." The average price target is $52.00, which represents a potential upside of over 9% from the current share price.

Risks to Consider

There are some risks to consider before investing in Pfizer. First, the company's share price is sensitive to news about its new drugs. If a new drug fails to meet expectations, the share price could decline.

Second, Pfizer faces competition from other pharmaceutical companies. If a competitor launches a new drug that is more effective or less expensive than Pfizer's drugs, the company's sales could decline.

Third, the healthcare industry